Silence Therapeutics plc (SLNCF)
- Business Wire
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
LONDON, May 16, 2024--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the first quarter ended March 31, 2024 and reviewed recent business highlights.
- Business Wire
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
LONDON, April 30, 2024--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20th at 2:30 p.m. ET.
- Business Wire
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
LONDON, April 29, 2024--Silence Therapeutics plc (Nasdaq: SLN) ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, who has served as an independent member of Silence’s Board of Directors (the "Board") since 2015, informed the Company that he will retire from the Board, effective May 1, 2024.
